<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095145</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00695</org_study_id>
    <secondary_id>NCI-2014-00695</secondary_id>
    <secondary_id>N01-CN-2012-00033</secondary_id>
    <secondary_id>CO11378</secondary_id>
    <secondary_id>UWI2013-00-01</secondary_id>
    <secondary_id>N01CN00033</secondary_id>
    <secondary_id>N01CN35153</secondary_id>
    <secondary_id>P30CA014520</secondary_id>
    <nct_id>NCT02095145</nct_id>
  </id_info>
  <brief_title>Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance</brief_title>
  <official_title>A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomxâ„¢ in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in
      patients with prostate cancer that is limited to a certain part of the body (localized), who
      have chosen observation as their treatment plan. The use of pomegranate-extract pill may slow
      disease progression in patients with localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the effect of pomegranate fruit extract (PFE) 1000 mg, taken daily for 1
      year, on the plasma levels of insulin-like growth factor (IGF-1) from baseline to end of
      study (52 weeks) in participants undergoing active surveillance (AS) for early stage prostate
      cancer.

      SECONDARY OBJECTIVES:

      I. To assess compliance with a once daily oral administration of PFE versus placebo over a
      52-week period of time.

      II. To assess the toxicity of PFE vs. placebo when taken daily for 52 weeks (+/- 1 week).

      III. To compare and correlate the effect of 52 weeks of daily dosing with PFE vs placebo on
      the end of study biopsy results including the presence or absence of tumor, the extent of
      tumor and Gleason scores.

      IV. To compare and correlate the modulation of the following biomarkers with response to PFE
      versus placebo in three areas of interest: tissue from a completely benign biopsy core, tumor
      tissue from a positive core, and normal tissue adjacent to tumor from a positive core;
      plasma: insulin-like growth factor 1/IGF binding protein 3 ratio (IGF-1/IGFBP-3 ratio);
      prostate tissue (normal and abnormal): apoptosis (CASPASE 3), Ki-67, 8OHdG, IGF-1R, androgen
      receptor, IGF-1, IGFBP-3, prostate specific antigen (PSA).

      V. Measure PFE constituents/metabolites in plasma and urine for evidence of accumulation
      (trough levels): ellagic acid, dimethyl ellagic acid, dimethyl ellagic acid glucuronide
      (DMEAG), urolithin A, urolithin A-glucuronide, urolithin B and urolithin B-glucuronide.

      VI. Measure PSA doubling time (PSA DT) in serum, using the calculation provided on the
      Memorial Sloan Kettering Cancer Center website.

      VII. To assess the feasibility of cancer chemoprevention trials in a population of men
      undergoing active surveillance for prostate cancer.

      VIII. Measurement of serum testosterone.

      OUTLINE: Patients are randomized to 1 of 2 groups.

      GROUP I: Patients receive pomegranate-extract pill orally (PO) once daily (QD) for 52 weeks
      (+/- 1 week).

      GROUP II: Patients receive placebo PO QD for 52 weeks (+/- 1 week).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2014</start_date>
  <completion_date type="Actual">September 26, 2019</completion_date>
  <primary_completion_date type="Actual">January 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma IGF-1 From Baseline to Post-Treatment</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>The primary endpoint for modulation of intermediate endpoint biomarkers will be the change in the plasma levels of IGF-1 by a quantitative assay (ELISA) from pre-study to post-treatment. The difference between these time points for the placebo group and the pomegranate fruit extract (PFE) group will be tested using a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance: Number of Participants Who Took Study Drug Per Protocol</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summarized by treatment arm with descriptive statistics, and tested for imbalance using Wilcoxon rank-sum test. Reported for each visit per protocol at Week 13, Week 26, Week 39, and Week 52 (end of study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events Graded Per Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Patient toxicity throughout the study will be summarized in several ways; the presence or absence of any toxicity, worst CTCAE grade, and strongest investigator-defined relationship will all be examined and characterized by treatment arm, and analyzed appropriately (Wilcoxon rank-sum for ordinal data, Fisher's exact test for dichotomous data, and log rank test for time to event data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Biomarker Levels From Baseline: IGFBP-3</measure>
    <time_frame>Week 13, Week 26, Week 39, Week 52</time_frame>
    <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Biomarker Levels From Baseline: IGF-1/GFBP-3</measure>
    <time_frame>Week 13, Week 26, Week 39, Week 52</time_frame>
    <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Serum Prostate Specific Antigen (PSA) From Baseline</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Testosterone</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen Doubling Time (PSA DT)</measure>
    <time_frame>up to 52 Weeks</time_frame>
    <description>PSA DT will be determined from PSA values obtained during study participation (baseline and weeks 13, 26, 39 and 52). The secondary endpoint of PSA DT is based on the value at study completion (week 52 or at point of early termination). However, PSA DT will be determined starting at week 26 (the earliest time point with 3 values) and week 39 and recorded. PSA doubling time is a measure based on the slope of the PSA at multiple time points. If the slope is relatively flat, the predicted doubling time could be far beyond the length of the actual study. As such, the value is not limited to the time frame over which data is collected from the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: PSA</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: IGF-1</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: IGFBP-3</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: CASP3</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: Ki-67</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: IGF-Rb</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: 8OHdG</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Biomarker Levels: AR</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Pomegranate Fruit Extract (PFE) Constituents/Metabolites: Urolithin A</measure>
    <time_frame>Change from Baseline at Week 13, Week 26, Week 39, and Week 52</time_frame>
    <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of PFE Constituents/Metabolites: Urolithin B</measure>
    <time_frame>Change from Baseline at Week 13, Week 26, Week 39, and Week 52</time_frame>
    <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gleason Score</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>The Gleason Score is a grading system used to determine the aggressiveness of prostate cancer, scored 1-5 with 1 being healthy tissue and 5 being abnormal. Prostate cancers are assigned 2 scores to define the 2 most prevalent tissue types. They are added together (total range of 2-10). Typical scores fall between 6-10, the higher the overall score, the more likely the cancer will spread.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biopsy Tumor Involvement on Prostate Biopsy</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Change in the length of biopsy cores that contained cancerous tissue from Baseline to end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>PSA Level Less Than or Equal to Fifteen</condition>
  <condition>PSA Level Less Than Ten</condition>
  <condition>Stage I Prostate Cancer AJCC v7</condition>
  <condition>Stage II Prostate Cancer AJCC v7</condition>
  <condition>Stage IIA Prostate Cancer AJCC v7</condition>
  <condition>Stage IIB Prostate Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <arm_group_label>Group II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <arm_group_label>Group II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomegranate-Extract Pill</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <other_name>POMx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have had a standard-of-care biopsy within 13 months of the baseline
             study visit and must have been diagnosed with low-grade, clinically localized prostate
             cancer (Gleason score =&lt; 3+3 with a PSA at baseline &lt; 10 ng/ml in participants &lt; 70
             years of age, OR Gleason score =&lt; 3+4 with a PSA at baseline =&lt; 15 ng/ml in
             participants &gt;= 70 years of age); eligible participants will be those men who are able
             and willing to undergo AS with PSA monitoring and a scheduled biopsy performed at the
             end of the study

          -  No concurrent treatment (hormonal, radiation or systemic chemotherapy) for prostate
             cancer during study enrollment is planned (unless participants demonstrate clinical
             evidence of prostate cancer progression such as symptoms, physical exam findings, a
             rapidly increasing PSA, or radiologic findings which confirm disease progression)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1

          -  White blood cells (WBC) &gt;= 3000/mm^3

          -  Platelets &gt;= 100,000 mm^3

          -  Hemoglobin &gt;= 10 g/dL

          -  Total bilirubin =&lt; 1.5 x upper limit of institutional normal

          -  Alkaline phosphatase =&lt; 1.5 x upper limit of institutional normal

          -  Aspartate aminotransferase (AST) =&lt; 1.5 x upper limit of institutional normal

          -  Alanine aminotransferase (ALT) =&lt; 1.5 x upper limit of institutional normal

          -  Serum creatinine within 1.5 x upper limit of institutional normal

          -  Sodium 135-144 mmol/L (inclusive)

          -  Potassium 3.2-4.8 mmol/L (inclusive)

          -  Participants will be required to use a medically-approved method of birth control or
             abstinence if their sexual partner is of child-bearing potential

          -  Participants must be willing to forego foods, beverages and supplements containing
             pomegranate for the duration of the study

          -  Ability to understand, and the willingness to sign, a written informed consent
             document

        Exclusion Criteria:

          -  Any prior surgery to the prostate within 30 days of baseline procedures; NOTE:
             Biopsies are not considered surgeries

          -  Evidence of other cancer(s) (excluding non-melanoma skin cancer) within last 5 years

          -  Prior pelvic radiation for any reason

          -  Participants cannot be taking 5-alpha-reductase inhibitors while on study or within 6
             months of the baseline study visit

          -  Participants may not be taking carbamazepine (tegretol)

          -  Participants may not be receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to PFE

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Any significant cardiac event(s) within the 12 months prior to registration, such as
             episode(s) of symptomatic congestive heart failure, myocardial infarction, unstable
             angina pectoris or persistent, stable angina pectoris, or cardiac arrhythmia requiring
             medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F Jarrard</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <results_first_submitted>November 20, 2019</results_first_submitted>
  <results_first_submitted_qc>January 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02095145/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>38 participants consented, only 30 eligible to start study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group I (Pomegranate-extract Pill)</title>
          <description>Patients receive pomegranate-extract pill orally once a day for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Group II (Placebo)</title>
          <description>Patients receive placebo orally once a day for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I (Pomegranate-extract Pill)</title>
          <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Group II (Placebo)</title>
          <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Participant Age</title>
              <category_list>
                <category>
                  <title>18-64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65 years or older</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>The final report for this study contains data for participant 'gender', the study team would like to note this for consistency.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) 0 = Fully active, able to carry on all pre-disease performance without restriction
1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ECOG 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECOG 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140.71" lower_limit="115.00" upper_limit="162.00"/>
                    <measurement group_id="B2" value="139.80" lower_limit="116.00" upper_limit="179.00"/>
                    <measurement group_id="B3" value="140.24" lower_limit="115.00" upper_limit="179.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.64" lower_limit="73.00" upper_limit="95.00"/>
                    <measurement group_id="B2" value="83.60" lower_limit="71.00" upper_limit="108.00"/>
                    <measurement group_id="B3" value="82.66" lower_limit="71.00" upper_limit="108.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Temperature</title>
          <units>degrees Fahrenheit</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.81" lower_limit="96.06" upper_limit="98.96"/>
                    <measurement group_id="B2" value="97.62" lower_limit="96.90" upper_limit="98.40"/>
                    <measurement group_id="B3" value="97.71" lower_limit="96.06" upper_limit="98.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.00" lower_limit="55.00" upper_limit="91.00"/>
                    <measurement group_id="B2" value="68.13" lower_limit="52.00" upper_limit="87.00"/>
                    <measurement group_id="B3" value="71.45" lower_limit="52.00" upper_limit="91.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174.73" lower_limit="162.56" upper_limit="190.50"/>
                    <measurement group_id="B2" value="177.23" lower_limit="160.02" upper_limit="188.00"/>
                    <measurement group_id="B3" value="176.02" lower_limit="160.02" upper_limit="190.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.92" lower_limit="67.59" upper_limit="102.40"/>
                    <measurement group_id="B2" value="94.53" lower_limit="67.20" upper_limit="124.74"/>
                    <measurement group_id="B3" value="91.82" lower_limit="67.20" upper_limit="124.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.15" lower_limit="23.12" upper_limit="33.53"/>
                    <measurement group_id="B2" value="29.91" lower_limit="25.33" upper_limit="35.31"/>
                    <measurement group_id="B3" value="29.55" lower_limit="23.12" upper_limit="35.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History or Baseline Presence of Disease / Abnormality</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Eyes/Ears/Neck/Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitalia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>The Gleason Score is a grading system used to determine the aggressiveness of prostate cancer, scored 1-5 with 1 being healthy tissue and 5 being abnormal. Prostate cancers are assigned 2 scores to define the 2 most prevalent tissue types. They are added together (total range of 2-10). Typical scores fall between 6-10, the higher the overall score, the more likely the cancer will spread.</description>
          <units>scores on a scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>3+3=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+4=7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma IGF-1 From Baseline to Post-Treatment</title>
        <description>The primary endpoint for modulation of intermediate endpoint biomarkers will be the change in the plasma levels of IGF-1 by a quantitative assay (ELISA) from pre-study to post-treatment. The difference between these time points for the placebo group and the pomegranate fruit extract (PFE) group will be tested using a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma IGF-1 From Baseline to Post-Treatment</title>
          <description>The primary endpoint for modulation of intermediate endpoint biomarkers will be the change in the plasma levels of IGF-1 by a quantitative assay (ELISA) from pre-study to post-treatment. The difference between these time points for the placebo group and the pomegranate fruit extract (PFE) group will be tested using a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.12" spread="21.22"/>
                    <measurement group_id="O2" value="8.54" spread="23.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.190</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.211</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance: Number of Participants Who Took Study Drug Per Protocol</title>
        <description>Summarized by treatment arm with descriptive statistics, and tested for imbalance using Wilcoxon rank-sum test. Reported for each visit per protocol at Week 13, Week 26, Week 39, and Week 52 (end of study).</description>
        <time_frame>Up to 1 year</time_frame>
        <population>One participant has no compliance values for weeks 26 and 39.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance: Number of Participants Who Took Study Drug Per Protocol</title>
          <description>Summarized by treatment arm with descriptive statistics, and tested for imbalance using Wilcoxon rank-sum test. Reported for each visit per protocol at Week 13, Week 26, Week 39, and Week 52 (end of study).</description>
          <population>One participant has no compliance values for weeks 26 and 39.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events Graded Per Common Terminology Criteria for Adverse Events (CTCAE)</title>
        <description>Patient toxicity throughout the study will be summarized in several ways; the presence or absence of any toxicity, worst CTCAE grade, and strongest investigator-defined relationship will all be examined and characterized by treatment arm, and analyzed appropriately (Wilcoxon rank-sum for ordinal data, Fisher's exact test for dichotomous data, and log rank test for time to event data).</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Graded Per Common Terminology Criteria for Adverse Events (CTCAE)</title>
          <description>Patient toxicity throughout the study will be summarized in several ways; the presence or absence of any toxicity, worst CTCAE grade, and strongest investigator-defined relationship will all be examined and characterized by treatment arm, and analyzed appropriately (Wilcoxon rank-sum for ordinal data, Fisher's exact test for dichotomous data, and log rank test for time to event data).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Severe) or Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Biomarker Levels From Baseline: IGFBP-3</title>
        <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Week 13, Week 26, Week 39, Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Biomarker Levels From Baseline: IGFBP-3</title>
          <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change Baseline to Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-102.91" spread="501.07"/>
                    <measurement group_id="O2" value="-195.57" spread="592.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline to Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.55" spread="560.69"/>
                    <measurement group_id="O2" value="99.74" spread="652.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline to Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-309.11" spread="455.91"/>
                    <measurement group_id="O2" value="89.34" spread="381.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline to Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-137.67" spread="363.48"/>
                    <measurement group_id="O2" value="-0.39" spread="498.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 13 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 26 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.711</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 39 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 52 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.445</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Biomarker Levels From Baseline: IGF-1/GFBP-3</title>
        <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Week 13, Week 26, Week 39, Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Biomarker Levels From Baseline: IGF-1/GFBP-3</title>
          <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change Baseline to Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline to Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="-0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline to Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline to Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 13 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.743</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 26 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.305</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 39 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 52 p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.395</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Serum Prostate Specific Antigen (PSA) From Baseline</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Statistician notes that serum PSA data is missing for one participant in the pomegranate extract arm for all time points, missing for another in the pomegranate arm at week 39, and one from the placebo arm at week 39.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Serum Prostate Specific Antigen (PSA) From Baseline</title>
          <population>Statistician notes that serum PSA data is missing for one participant in the pomegranate extract arm for all time points, missing for another in the pomegranate arm at week 39, and one from the placebo arm at week 39.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change Baseline to Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="4.78"/>
                    <measurement group_id="O2" value="-1.05" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="4.67"/>
                    <measurement group_id="O2" value="-0.77" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="5.52"/>
                    <measurement group_id="O2" value="-0.29" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="5.89"/>
                    <measurement group_id="O2" value="-0.08" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline PSA to Week 13</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.743</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline PSA to Week 26</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.527</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline PSA to Week 39</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.879</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline PSA to Week 52</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.810</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Testosterone</title>
        <time_frame>up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill orally once a day for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo orally once a day for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Testosterone</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.37" spread="5.23"/>
                    <measurement group_id="O2" value="9.73" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.43" spread="10.48"/>
                    <measurement group_id="O2" value="12.61" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" spread="19.84"/>
                    <measurement group_id="O2" value="9.27" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of both arms at baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.556</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of both arms at Week 26</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.647</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of both arms at end of study, week 52</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Antigen Doubling Time (PSA DT)</title>
        <description>PSA DT will be determined from PSA values obtained during study participation (baseline and weeks 13, 26, 39 and 52). The secondary endpoint of PSA DT is based on the value at study completion (week 52 or at point of early termination). However, PSA DT will be determined starting at week 26 (the earliest time point with 3 values) and week 39 and recorded. PSA doubling time is a measure based on the slope of the PSA at multiple time points. If the slope is relatively flat, the predicted doubling time could be far beyond the length of the actual study. As such, the value is not limited to the time frame over which data is collected from the participant.</description>
        <time_frame>up to 52 Weeks</time_frame>
        <population>One of the participant's PSA values were 'non-detectable', therefore PSA observations could not be calculated for that participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen Doubling Time (PSA DT)</title>
          <description>PSA DT will be determined from PSA values obtained during study participation (baseline and weeks 13, 26, 39 and 52). The secondary endpoint of PSA DT is based on the value at study completion (week 52 or at point of early termination). However, PSA DT will be determined starting at week 26 (the earliest time point with 3 values) and week 39 and recorded. PSA doubling time is a measure based on the slope of the PSA at multiple time points. If the slope is relatively flat, the predicted doubling time could be far beyond the length of the actual study. As such, the value is not limited to the time frame over which data is collected from the participant.</description>
          <population>One of the participant's PSA values were 'non-detectable', therefore PSA observations could not be calculated for that participant.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.01" spread="560.33"/>
                    <measurement group_id="O2" value="125.63" spread="282.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.580</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: PSA</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: PSA</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>normalized optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.42"/>
                    <measurement group_id="O2" value="0.04" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.09"/>
                    <measurement group_id="O2" value="0.16" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.39"/>
                    <measurement group_id="O2" value="0.25" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Benign core p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.344</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjacent core p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tumor core p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: IGF-1</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: IGF-1</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>normalized optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Nuc Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="1.65"/>
                    <measurement group_id="O2" value="0.57" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="2.78"/>
                    <measurement group_id="O2" value="1.74" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="2.39"/>
                    <measurement group_id="O2" value="1.06" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.35"/>
                    <measurement group_id="O2" value="0.21" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="1.77"/>
                    <measurement group_id="O2" value="1.47" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="1.64"/>
                    <measurement group_id="O2" value="1.10" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="1.45"/>
                    <measurement group_id="O2" value="0.35" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="2.17"/>
                    <measurement group_id="O2" value="1.59" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="1.99"/>
                    <measurement group_id="O2" value="1.06" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Benign (Nuc)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.304</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Adjacent (Nuc)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.230</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Tumor (Nuc)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.298</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Benign (Cyt)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.247</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Adjacent (Cyt)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Tumor (Cyt)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Benign (Cell)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.247</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Adjacent (Cell)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: IGF-1 Tumor (Cell)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: IGFBP-3</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: IGFBP-3</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>normalized optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Nuc Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="2.77"/>
                    <measurement group_id="O2" value="0.78" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="1.51"/>
                    <measurement group_id="O2" value="1.55" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="2.21"/>
                    <measurement group_id="O2" value="1.75" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.56"/>
                    <measurement group_id="O2" value="0.52" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="1.39"/>
                    <measurement group_id="O2" value="0.67" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.90"/>
                    <measurement group_id="O2" value="0.76" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="2.02"/>
                    <measurement group_id="O2" value="0.68" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="1.62"/>
                    <measurement group_id="O2" value="1.07" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="1.48"/>
                    <measurement group_id="O2" value="1.24" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.297</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: CASP3</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: CASP3</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>normalized optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Nuc Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="1.74"/>
                    <measurement group_id="O2" value="0.57" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="1.06"/>
                    <measurement group_id="O2" value="0.38" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="1.06"/>
                    <measurement group_id="O2" value="0.04" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="1.43"/>
                    <measurement group_id="O2" value="-0.01" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="1.31"/>
                    <measurement group_id="O2" value="0.54" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="1.66"/>
                    <measurement group_id="O2" value="-0.00" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="1.52"/>
                    <measurement group_id="O2" value="0.23" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="1.16"/>
                    <measurement group_id="O2" value="0.43" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="1.35"/>
                    <measurement group_id="O2" value="0.01" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.713</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.452</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.713</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.344</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.713</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: Ki-67</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: Ki-67</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.50"/>
                    <measurement group_id="O2" value="0.06" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.36"/>
                    <measurement group_id="O2" value="-0.53" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline:Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" spread="12.11"/>
                    <measurement group_id="O2" value="1.31" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.865</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: IGF-Rb</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: IGF-Rb</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>normalized optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Nuc Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="1.08"/>
                    <measurement group_id="O2" value="-0.52" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.24"/>
                    <measurement group_id="O2" value="0.32" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="2.00"/>
                    <measurement group_id="O2" value="0.88" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="1.35"/>
                    <measurement group_id="O2" value="-0.48" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.71"/>
                    <measurement group_id="O2" value="0.80" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.45"/>
                    <measurement group_id="O2" value="0.58" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="1.21"/>
                    <measurement group_id="O2" value="-0.52" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.85"/>
                    <measurement group_id="O2" value="0.56" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="1.63"/>
                    <measurement group_id="O2" value="0.73" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Nuc Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Nuc Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.903</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Nuc Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Cyt Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.269</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Cyt Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Cyt Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Cell Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.425</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Cell Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.270</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Cell Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: 8OHdG</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: 8OHdG</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Measurements for each are per nuclear (&quot;Nuc&quot; in results), cytoplasmic (&quot;Cyt&quot; in results), and cellular (&quot;Cell&quot; in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>normalized optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Nuc Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.15"/>
                    <measurement group_id="O2" value="-0.02" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.13"/>
                    <measurement group_id="O2" value="0.07" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Nuc Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.08"/>
                    <measurement group_id="O2" value="0.07" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.47"/>
                    <measurement group_id="O2" value="0.21" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.45"/>
                    <measurement group_id="O2" value="0.47" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cyt Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.33"/>
                    <measurement group_id="O2" value="0.41" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.43"/>
                    <measurement group_id="O2" value="0.09" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.43"/>
                    <measurement group_id="O2" value="0.20" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Cell Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.28"/>
                    <measurement group_id="O2" value="0.19" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Nuc Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cyt Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change From Baseline: Cell Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Biomarker Levels: AR</title>
        <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Biomarker Levels: AR</title>
          <description>Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core (&quot;benign&quot; in results), tumor tissue from a positive core (&quot;tumor&quot; in results), and normal tissue adjacent to tumor from a positive core (&quot;adjacent&quot; in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <population>The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).</population>
          <units>normalized optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From Baseline: Benign</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="1.07"/>
                    <measurement group_id="O2" value="-0.55" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Adjacent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.60"/>
                    <measurement group_id="O2" value="1.02" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline: Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.15"/>
                    <measurement group_id="O2" value="0.38" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Benign p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Adjacent p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline: Tumor p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Pomegranate Fruit Extract (PFE) Constituents/Metabolites: Urolithin A</title>
        <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Change from Baseline at Week 13, Week 26, Week 39, and Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Pomegranate Fruit Extract (PFE) Constituents/Metabolites: Urolithin A</title>
          <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13491.88" spread="25612.57"/>
                    <measurement group_id="O2" value="-8722.87" spread="32254.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29686.34" spread="38169.43"/>
                    <measurement group_id="O2" value="-7119.63" spread="33532.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41322.95" spread="80948.44"/>
                    <measurement group_id="O2" value="-3688.76" spread="32749.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21622.01" spread="29672.67"/>
                    <measurement group_id="O2" value="-4882.23" spread="17075.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 13</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 26</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 39</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 52</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of PFE Constituents/Metabolites: Urolithin B</title>
        <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
        <time_frame>Change from Baseline at Week 13, Week 26, Week 39, and Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of PFE Constituents/Metabolites: Urolithin B</title>
          <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="156.86" spread="603.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="709.24" spread="2653.74"/>
                    <measurement group_id="O2" value="801.40" spread="2807.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1389.82" spread="4536.11"/>
                    <measurement group_id="O2" value="216.54" spread="838.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 13</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 26</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 39</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.620</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Week 52</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.536</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gleason Score</title>
        <description>The Gleason Score is a grading system used to determine the aggressiveness of prostate cancer, scored 1-5 with 1 being healthy tissue and 5 being abnormal. Prostate cancers are assigned 2 scores to define the 2 most prevalent tissue types. They are added together (total range of 2-10). Typical scores fall between 6-10, the higher the overall score, the more likely the cancer will spread.</description>
        <time_frame>Baseline to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gleason Score</title>
          <description>The Gleason Score is a grading system used to determine the aggressiveness of prostate cancer, scored 1-5 with 1 being healthy tissue and 5 being abnormal. Prostate cancers are assigned 2 scores to define the 2 most prevalent tissue types. They are added together (total range of 2-10). Typical scores fall between 6-10, the higher the overall score, the more likely the cancer will spread.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <title>0+0=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3+3=6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3+4=7</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery Visit (52 Weeks)</title>
              <category_list>
                <category>
                  <title>0+0=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3+3=6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3+4=7</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biopsy Tumor Involvement on Prostate Biopsy</title>
        <description>Change in the length of biopsy cores that contained cancerous tissue from Baseline to end of study.</description>
        <time_frame>Baseline to 1 year</time_frame>
        <population>One participant has a baseline measurement but does not have an end of study measurement, a change in the biopsy tumor involvement for this participant is therefore not possible to calculate.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (Pomegranate-extract Pill)</title>
            <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biopsy Tumor Involvement on Prostate Biopsy</title>
          <description>Change in the length of biopsy cores that contained cancerous tissue from Baseline to end of study.</description>
          <population>One participant has a baseline measurement but does not have an end of study measurement, a change in the biopsy tumor involvement for this participant is therefore not possible to calculate.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="8.09"/>
                    <measurement group_id="O2" value="1.88" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Tumor Volume from baseline to end of study per arm</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.231</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group I (Pomegranate-extract Pill)</title>
          <description>Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Pomegranate-Extract Pill: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Group II (Placebo)</title>
          <description>Patients receive placebo PO QD for 52 weeks (+/- 1 week).
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and Medical Procedures, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Post-Operative Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders, other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders, Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations, Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Post-Operative Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cholesterol High</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint Range of Motion Decreased Lumbar Spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cystitis Noninfective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Renal and Urinary Disorders, Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Renal Calculi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary Tract Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary Urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and Subcutaneous Tissue Disorders, Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and Medical Procedures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Jarrard</name_or_title>
      <organization>University of Wisconsin Carbone Cancer Center</organization>
      <phone>608-262-0759</phone>
      <email>jarrard@urology.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

